z-logo
open-access-imgOpen Access
Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March–April 2021
Author(s) -
Heidi L Moline,
Amelia A. Keaton,
Whitney Rice,
Jasmine Varghese,
Li Deng,
Ansley Waters,
Anna Barringer,
Devonne Winston,
Virgie Fields,
Kara Jacobs Slifka,
Jennifer R. Verani,
Stephanie J. Schrag,
John A. Jernigan,
Jacqueline E. Tate,
Katherine E. Fleming-Dutra
Publication year - 2022
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciac526
Subject(s) - medicine , outbreak , context (archaeology) , covid-19 , coronavirus , vaccination , virology , betacoronavirus , disease , immunology , infectious disease (medical specialty) , biology , paleontology
In April 2021, we assessed mRNA vaccine effectiveness (VE) in the context of a COVID-19 outbreak in a skilled nursing facility. Among 28 cases, genomic sequencing was performed on 4 specimens on 4 different patients, and all were classified by sequence analysis as the Beta (B.1.351) variant. Adjusted VE among residents was 65% (95% confidence interval: 25-84%). These findings underscore the importance of vaccination for prevention of COVID-19 in skilled nursing facilities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom